Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Applied Functional Genomics

Prof. Dr. Claudia Scholl

Multicolor immunofluorescence staining of different mouse lung epithelial cells
© dkfz.de

Human cancers are characterized by the acquisition of mutations, such as single-nucleotide variants, small insertions/deletions or copy number alterations. While many of these lesions have been associated with biological characteristics of tumors, the contribution of most mutations to cancer development is unclear. In addition, somatically acquired genetic alterations result in rewiring of intracellular signaling networks during malignant transformation, thereby inducing secondary dependencies on genes that are not directly affected by mutations. Understanding the biological relevance of cancer mutations and their associated secondary dependencies is essential for the successful implementation of individualized cancer therapies. The mission of our laboratory is to find and characterize such specific vulnerabilities in cancer cells that can be exploited for the development of targeted therapies. To achieve this goal, we use a broad spectrum of molecular and cell biological technologies, such as gene manipulation using RNAi, CRISPRi, and CRISPR/Cas9 gene editing on small and large scale in combination with the analysis of diverse in vitro and in vivo phenotypic readouts (e.g. automated microscopy and flow cytometry, protein biochemistry, genetically-engineered mice). We are currently pursuing the following research areas:

Functional characterization of new cancer mutations:
we are systematically and comprehensively mapping the function of rare and uncharacterized cancer mutations, which will provide novel mechanistic insights into key cellular pathways and help guide the translation of genomic information into clinical application.

Identification and characterization of secondary gene dependencies:
we are using large scale CRISPR screening to uncover secondary dependencies in mesenchymal malignancies (e.g. soft tissue sarcoma and chordoma), we work towards understanding specific vulnerabilities in acute myeloid leukemia, and we characterize epigenetic dependencies in mutant KRAS-driven cancer.

Study of stem and progenitor cells in the murine lung:
we are combining newly developed genetically engineered mouse models and single-cell RNA sequencing to identify normal and malignant lung epithelial stem cells and to delineate the regulatory pathways within these cell types.

Contact

Prof. Dr. Claudia Scholl
Applied Functional Genomics (B290)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 581
69120 Heidelberg
Tel: +49 6221 42 1636

Selected Publications

  • Trautmann M & Cheng YY et al. (2019). Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Mol Med 11: e9889.
  • Rudat S et al. (2018). RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia 32:2189-2202.
  • Martins LR & Bung RK et al. (2018). Stk33 is required for spermatid differentiation and male fertility in mice. Dev Biol 433:84-93.
  • Placke T et al. (2014). Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood 124:13-23.
to top
powered by webEdition CMS